Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study

Birth Defects Research

Volumn 109, Issue 15, 2017, Pages 1196-1203

  Diav Citrin, Orna ^a,b   Shechtman, Svetlana ^a   Zvi, Naama ^a   Finkel Pekarsky, Victoriya ^a   Ornoy, Asher ^b  

^a MINISTRY OF HEALTH   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

congenital anomalies; epilepsy; Lamotrigine; mood disorders; pregnancy

Indexed keywords

LAMOTRIGINE; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADULT; ARTICLE; BODY TEMPERATURE DISORDER; BRADYCARDIA; BRAIN MALFORMATION; CLEFT PALATE; CLUBFOOT; COMPARATIVE STUDY; CONGENITAL HYPOTHYROIDISM; CONGENITAL MALFORMATION; CONTROLLED STUDY; CRYPTORCHISM; DOSE RESPONSE; DRUG SAFETY; EPILEPSY; FEMALE; FETUS ECHOGRAPHY; HEART SEPTUM DEFECT; HIP DYSPLASIA; HUMAN; INGUINAL HERNIA; JAUNDICE; MAJOR CLINICAL STUDY; MENTAL DISEASE; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; TREATMENT INDICATION; CHEMICALLY INDUCED; CONGENITAL DISORDER; DRUG INDUCED MALFORMATION; FIRST TRIMESTER PREGNANCY; MALE; MOUTH DISEASE; PRENATAL EXPOSURE; REGISTER;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CONGENITAL ABNORMALITIES; FEMALE; HUMANS; MALE; MOUTH ABNORMALITIES; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; REGISTRIES; TRIAZINES;

EID: 85026872934     PISSN: None     EISSN: 24721727     Source Type: Journal    
DOI: 10.1002/bdr2.1058     Document Type: Article

References (37)

1. Behjati-Ardani M, Golshan M, Akhavan-Karbasi S, et al. 2016. The clinical course of patients with atrial septal defects. Iran J Pediatr 26:e4649.
2. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DG, et al. 1986. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 27:248–254.
3. Calabrese JR, Bowden CL, Sachs GS, et al. 1999. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79–88.
4. Clark CT, Klein AM, Perel JM, et al. 2013. Lamotrigine dosing for pregnant women with bipolar disorder. Am J Psychiatry 170:1240–1247.
5. Cohen MJ, Meador KJ, Browning N, et al. 2013. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav 29:308–315.
6. Cunnington MC, Weil JC, Messenheimer JA, et al. 2011. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 76:1817–1823.
7. de Haan GJ, Edelbroek P, Segers J, et al. 2004. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 63:571–573.
8. EUROCAT Guide 1.4. Chapter 3 - Coding and Classification. Available at: http://www.eurocat-network.eu/aboutus/datacollection/guidelinesforregistration/guide1_4. Accessed March 28, 2017.
9. Farmen AH, Grundt J, Tomson T, et al. 2015. Intrauterine growth retardation in foetuses of women with epilepsy. Seizure 28:76–80.
10. Gerard EE, Meador KJ. 2015. An update on maternal use of antiepileptic medications in pregnancy and neurodevelopment outcomes. J Pediatr Genet 4:94–110.
11. Hanslik A, Pospisil U, Salzer-Muhar U, et al. 2006. Predictors of spontaneous closure of isolated secundum atrial septal defect in children: a longitudinal study. Pediatrics 118:1560–1565.
12. Hernández-Díaz S, Smith CR, Shen A, et al. 2012. Comparative safety of antiepileptic drugs during pregnancy. Neurology 78:1692–1699.
13. Holmes LB. 1999. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 59:1–2.
14. Holmes LB, Baldwin EJ, Smith CR, et al. 2008. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70:2152–2158.
15. Holmes LB, Hernandez-Diaz S. 2012. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol 94:599–606.
16. Holmes LB, Mittendorf R, Shen A, et al. 2011. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 68:1275–1281.
17. Lees G, Leach MJ. 1993. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 612:190–199.
18. Manent JB, Jorquera I, Franco V, et al. 2008. Antiepileptic drugs and brain maturation: fetal exposure to lamotrigine generates cortical malformations in rats. Epilepsy Res 78:131–139.
19. Marchi NS, Azoubel R, Tognola WA. 2001. Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study. Arq Neuropsiquiatr 59:362–364.
20. Meador KJ, Penovich P, Baker GA, et al. 2009. Antiepileptic drug use in women of childbearing age. Epilepsy Behav 15:339–343.
21. Meador K, Reynolds MW, Crean S, et al. 2008. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81:1–13.
22. Meador KJ, Baker GA, Browning N, et al. 2013. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244–252.
23. Merks JH, van Karnebeek CD, Caron HN, Hennekam RC. 2003. Phenotypic abnormalities: terminology and classification. Am J Med Genet A 123A:211–230.
24. Mølgaard-Nielsen D, Hviid A. 2011. Newer-generation antiepileptic drugs and risk of major birth defects. JAMA 305:1996–2002.
25. Morrow J, Russell A, Guthrie E, et al. 2006. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77:193–198.
26. Ohman I, Vitols S, Tomson T. 2000. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 41:709–713.
27. Product Monograph. Lamictal®, GlaxoSmithKline Inc. 2016. Available at: http://ca.gsk.com/media/529318/lamictal.pdf. Accessed February 13, 2017.
28. Rasmussen SA, Olney RS, Holmes LB, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67:193–201.
29. Rihtman T, Parush S, Ornoy A. 2013. Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function. Reprod Toxicol 41:115–125.
30. Sabers A. 2012. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand 126:e1–e4.
31. Tomson T, Battino D. 2012. Teratogenic effects of antiepileptic drugs. Lancet Neurol 11:803–813.
32. Tomson T, Battino D, Bonizzoni E, et al. 2011. Lancet Neurol 10:609–617.
33. Tomson T, Ohman I, Vitols S. 1997. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 38:1039–1041.
34. Vajda FJ, Graham J, Roten A, et al. 2012. Teratogenicity of the newer antiepileptic drugs – the Australian experience. J Clin Neurosci 19:57–59.
35. Vajda FJ, Hitchcock AA, Graham J, et al. 2010. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 51:805–810.
36. Veiby G, Dalveit AK, Engelsen BA, Gilhus NE. 2014. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 261:579–588.
37. Veiby G, Daltveit AK, Schjølberg S, et al. 2013. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia 54:1462–1472.